title: Perioperative use of cyproterone acetate with transurethral resection of large prostate: preliminary results.
abstract: OBJECTIVE
  To assess the impact of short-term treatment with cyproterone acetate (CPA) on intraoperative and early postoperative complications of transurethral resection of relatively large prostate.
  
  
  METHODS
  We recruited patients with prostate size of 60-90 g and randomized them into two equal groups. The first one had 50 mg of CPA orally twice a day (bds) for 2 weeks before the operation and maintained it for an extra week postoperatively. The other group received placebo. All patients underwent monopolar transurethral prostatectomy (M-TURP) and the prostatic chips were stained for CD34 specific for nascent blood vessels.
  
  
  RESULTS
  Ninety-five patients were included. Mean patient age was 60.88±2.5 years and mean prostate size was 72.76±7.21 g. CPA was well tolerated with no serious adverse effects. The mean resection time and the mean weight of the resected tissue were comparable between the two groups. Intraoperative blood loss, fluid absorption, and blood loss per gram of resected tissue (259.47±78.27 mL, 787.38±300.56 mL, and 14.87±4.02 mL/g and 327.25±98.97 mL, 937.4±350.2 mL, and 17.08±5.55 mL/g, respectively) were significantly lower in the treatment group (p<0.05). In addition, excessive postoperative bleeding was encountered in one case in the treatment group and in seven in the control (p<0.05). Finally, the histopathological study revealed that the mean microvessel density in each of the suburethral portion and the hyperplastic nodules of the prostate was significantly lower in the CPA group (p<0.001).
  
  
  CONCLUSIONS
  The perioperative use of CPA with M-TURP of a relatively large prostate may help in decreasing the perioperative bleeding and fluid absorption that usually take place during this procedure.
authors.affiliation: Urology Department, Tanta University , Tanta, Egypt .
authors.forename: Osama Mostafa
authors.initials: OM
authors.lastname: El-Gamal
authors.forename: Tarek Ahmed
authors.initials: TA
authors.lastname: Gameel
authors.forename: Ayman
authors.initials: A
authors.lastname: Ghoneem
authors.forename: Mohamed Gaber
authors.initials: MG
authors.lastname: Soliman
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abo-El-Enen
authors.forename: Amr Abo
authors.initials: AA
authors.lastname: El-Hitham
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Rasheedy
authors.forename: Mohamed Ahmed
authors.initials: MA
authors.lastname: Elbendary
authors.forename: Magdy
authors.initials: M
authors.lastname: Sabaa
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D019990:Perioperative Care / Q000379:methods*; D011183:Postoperative Complications; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011467:Prostate / Q000473:pathology / Q000601:surgery*; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000379:methods*
chemical_list: D000726:Androgen Antagonists; D017373:Cyproterone Acetate